Serum levels of B cell-activating factor (BAFF) rise following rituximab (RTX) therapy in patients with rheumatoid arthritis (RA). Initiation of naive B cell return to the periphery and autoreactive B cell expansion leading to relapse after RTX may therefore be linked to interactions between BAFF and BAFF-binding receptors (BBR). Relationships between serum BAFF and BBR expression [(BAFFR, calcium signal modulating cyclophilic ligand interactor (TACI) and B cell maturation antigen (BCMA)] were determined on B cell subsets, defined using immunoglobulin (Ig)D/CD38. Twenty pre-RTX and 18 RA patients relapsing after B cell depletion were included. Results were analysed with respect to timing of relapse up to 7 months after peripheral B cell return (! 5 B cells/ll) and to serum BAFF levels. After B cell return, B cell populations from relapsing patients had significantly lower BAFFR 1 expression compared to HC and pre-RTX 
Introduction
The B cell maturation process is the result of complex interactions related to the antigen specificity and strength of signal through the B cell receptor (BCR) and B cell survival factors, in particular the B cell activating factor (BAFF)/APRIL (a proliferation-inducing ligand) axis. Results from murine studies have shown that co-ordinated expression of BAFF-binding receptors (BBRs); namely, BAFFR (BR3), transmembrane activator and calcium signal modulating cyclophilic ligand interactor (TACI) and B cell maturation antigen (BCMA), are key to the differentiation of B cells into immunoglobulin-secreting cells (ISC) [1] . The three BBRs are expressed differentially on B cells during development and also respond in contextdependent ways to BAFF/APRIL ligation [2] . In humans, BAFFR is expressed on the majority of B cells in the peripheral blood following exit from the bone marrow (BM) [3] . BAFFR binds only BAFF [4] . Occupation of BAFFR by BAFF in resting B cells is relatively constant and delivers prosurvival signals, particularly to early naive B cell populations [2, 5] . BAFFR expression decreases when B cells differentiate into ISC, and loss of BAFFR is thought to be necessary for the expression of BCMA on late-stage plasmablasts, although short-lived plasmablasts can express both BAFFR and BCMA [2] . Expression of BCMA seems to be restricted largely to mature plasma cells in the BM and secondary lymphoid organs. TACI is expressed on a subpopulation of activated naive B cells (< 25%), and increases with activation through T-dependent and -independent stimuli. TACI is expressed on virtually all memory B cells and variably on plasma cells. Signalling through TACI can result in both positive and negative regulation of antibody responses, but seems necessary for class-switch recombination [6] . Alternatively, signalling by agonists through TACI can attenuate CD40-and BAFFR-induced maturation to immunoglobulin (Ig) production through both T-dependent and -independent pathways [7] .
Following its first reported success in the treatment of patients with rheumatoid arthritis (RA) in 2001 [8] ,B cell depletion therapy (BCDT) based on the anti-CD20 agent rituximab (RTX) has proved to be both effective and relatively safe [9, 10] . Seropositive patients respond most favourably to BCDT [11] , supporting the hypothesis that both B cells and their daughter plasma cells play a role in the pathogenesis of RA [12] [13] [14] . When adequate levels of B cell depletion are attained with RTX, clinical benefit to RA patients can last for months or, in some cases, years. Return of naive B cells to the circulation seems necessary for clinical relapse in responding patients, but it is not necessarily linked to concurrent relapse [13, 15] , with flare delayed for many months after B cell reconstitution begins. The pattern of relapse on repeat treatment, whether occurring close to B cell reconstitution or later, tends to be constant in individual patients [16] . Onset of relapse is associated with differentiation towards ISC, as shown by rises in autoantibodies [17] , the CD27 1 memory phenotype [18, 19] and the presence of circulating plasmablasts [20, 21] . Results thus suggest that factors promoting B cell maturation either from newly generated immature B cells or the expansion of memory cells into ISC may be key to understanding mechanisms underlying clinical relapse [22, 23] .
Due to its importance for B cell survival and homeostasis, BAFF and expression of its receptors are considered to be key regulators of B cell recovery after rituximab [24, 25] . Serum BAFF levels increase after BCDT in patients with RA, sometimes remaining raised even after B cell return. We have shown previously that BAFFR expression [mean fluorescence intensity (MFI)] in naive and memory B cells, as defined using IgD/CD27, was reduced compared with baseline in B cells returning after BCDT in patients with RA and in patients with thrombotic thrombocytopaenic purpura (TTP) [18, 26] . In patients with TTP, long-term remission (> 60 months) was associated with persistently low BAFFR expression, limited differentiation to memory B cell phenotype and negative tests for autoantibodies to ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS-13).
The present study extends our previous observations in patients with RA to include transitional naive B cells and plasmablasts in phenotype analyses, using the IgD/CD38 classification [3, 27] . Four patients with RA were followed longitudinally and we also conducted a cross-sectional analysis of B cell phenotype and BBR expression in patients at key time-points within treatment cycles of RTX-based B cell depletion therapy. The relationship between serum BAFF levels at relapse and expression of each of the three BBRs as well as the B cell phenotype was determined. Results were also analysed on the basis of timing of clinical relapse after B cell return.
Materials and methods

Patients
Blood samples were obtained from five healthy controls (HC) and a total of 38 patients with a diagnosis of RA who fulfilled the 1987 revised American College of Rheumatology (ACR) criteria [28] . The cohort of patients with RA included 20 with severe active disease [disease activity score (DAS)28 > 5Á1], who were studied pre-rituximab (pre-RTX patients), including four patients followed longitudinally with sampling pre-RTX, at B cell return and up to 6 months post-B cell return, and 18 patients undergoing clinical relapse after response (DDAS > 1Á2) to one or more courses of BCDT (post-RTX patients). Clinical relapse was defined by (i) any return or increase of signs and symptoms caused by inflammation owing to RA (ii) with or without a rise in CRP [17] . Patients were all attending the Department of Rheumatology at University College London Hospital (UCLH) and treated on the basis of clinical need. BCDT consisted of two infusions of 1 g RTX. The study was approved by the UCLH Ethics Committee (08/H0715/ 18), and all patients gave informed consent before entering the study.
RA patients on RTX at UCLH are seen regularly at a dedicated clinic, where CD19 1 B cells are determined every 2-3 months, allowing us to distinguish depletion and repopulation time-points accurately. Post-RTX relapsing patients were divided into two groups depending on the time that relapse was noted after the first documented repopulation. Mean age for RA patients was 58 years (range 5 27-79) and mean disease duration was 12Á7 years (range 1 5 39). There were five male patients. Three pre-RTX patients were seronegative for both rheumatoid factor (RhF) and anti-citrullinated protein antibodies (ACPA); all post-RTX patients were seropositive either for RhF or ACPA. Median number of cycles for post-RTX relapsing patients was two (range 5 1-7).
Assessment of B cell depletion
The normal range for CD19 ). Expression of BBRs on each subset was analysed using anti-BAFFR-PE (11C1), anti-TACI-biotin with streptavidin PE and anti-BCMA-PE. All antibodies were purchased from BD Biosciences (San Jose, CA, USA), eBioscience (San Diego, CA, USA) or R&D Systems (Minneapolis, MN, USA).
Measurement of BAFF
Serum BAFF levels were quantified in healthy controls and RA patients, using Human Quantikine BAFF/BLyS Immunoassay ELISA kit (R&D Systems). Mean 6 3 standard deviations (SD) for normal sera (n 5 36) in this batch of kits was given as 1Á17 6 0Á78 ng/ml. Serum BAFF values above 1Á95 ng/ml were therefore regarded as elevated.
Statistical analysis
Frequencies of B cell subsets were compared using nonparametric Mann-Whitney U-test. Spearman's rank correlation statistics were used to determine any relationship between serum BAFF levels and expression (percentage of positive cells and MFI) of BBRs, length of time after repopulation or after RTX or between B cell repopulation and disease relapse. All analyses were with GraphPad Prism (San Diego, CA, USA). shows that virtually all CD19 gated B cells express BAFFR before RTX, although the patient had active disease. The percentage of BAFFR 1 B cells was reduced greatly after RTX at B cell return (Fig. 2b) , but showed some signs of recovery 3 months later (Fig. 2c) . In the histograms for each FACS plot in the series, BAFFR expression (MFI) in the CD19 population can be seen to remain reduced even at 3 months post-RTX. Results were similar in the three other patients followed longitudinally (data not shown). 
Results
B cell subpopulations in patients relapsing after RTX
BAFFR
1 IgD -resting memory B cells were similar to HC (Fig. 2d5) .
MFI for BAFFR expression was significantly lower in all subpopulations in post-RTX patients compared to HC and pre-RTX patients. BAFFR MFI was also significantly lower in patients 0-3 months after B cell return compared with those relapsing ! 4 months after initiation of reconstitution in all except IgD 1 resting memory B cells and plasmablasts.
TACI. Figure 3a -c shows flow cytometry plots and associated histograms of TACI expression on CD19
1 gated B cells from the same RA patient studied longitudinally, as shown in Fig. 2 , for BAFFR expression. The proportion of percentage of CD19 1 TACI 1 B cells in the lymphocyte gate was reduced greatly at B cell return, decreasing from nearly 10% pre-RTX to fewer than 1% (Fig. 3b) , but the percentage of TACI 1 B cells increased from < 1 to 3% by 3 months after B cell return (Fig. 3b,c) . Figure 3d (1-6) shows that the % TACI 1 B cells was low in naive but present on the majority of memory B cell populations, with lower levels than HC in all memory B cell subpopulations in patients relapsing ! 4 months after B cell return compared with HC. The percentage of TACI 1 post-GC and resting memory B cell compartments were also decreased significantly in those relapsing closest to B cell return (0-3 months) compared with HC, but no significant difference between percentage of TACI 1 B cells in RTX-treated patients analysed either 0-3 or ! 4 months after B cell return.
BCMA. Figure 4a shows results for BCMA expression on CD19
1 B cells on 20 RA patients before and 18 after RTX therapy compared with HC. CD38) in healthy controls (HC) and in pre-and post-RTX rheumatoid arthritis (RA) patients. Results for post-RTX patients were divided on the basis of proximity to first documented B cell return, as described in Fig. 1 . Lines on graphs represent median values and results were analysed using the Mann-Whitney U-test; *P < 0Á05; **P < 0Á01; ***P < 0Á001. [Colour figure can be viewed at wileyonlinelibrary.com] within the CD19 1 population and similar among all B cell subpopulations in all HC and patient groups, including plasmablasts, except for a weak but significantly decreased expression in IgD -resting memory B cells in patients relapsing 0-3 months after repopulation compared to pre-RTX patients (P < 0Á01) and in IgD 1 resting memory B cells in patients relapsing ! 4 months after RTX compared to pre-RTX patients (P < 0Á05).
Serum BAFF levels: relationships with B cell phenotype and BBR expression
As shown in Fig. 5a , median BAFF levels in pre-RTX patients (1Á43 ng/ml, range 5 0Á84-2Á39) were raised compared to HC (1Á10 ng/ml, range 5 0Á89-1Á24; P < 0Á05), although they remained largely within the normal range (< 1Á95 ng/ml). Median BAFF levels in post-RTX patients (1Á95 ng/ml; range 5 0Á96-6Á47) were raised significantly compared to HC and pre-RTX patients. We have found previously that BAFFR expression was reduced significantly on both naive and memory B cells (defined using IgD/CD27) in RA patients at relapse, regardless of serum BAFF levels [18] . Using linear regression, we also found no correlation between serum BAFF levels and absolute numbers or percentage of B cell subpopulations based on IgD/CD38 expression (data not shown). There was no significant correlation between serum BAFF levels and number of RTX cycles received (data not shown), nor with time after repopulation (Fig. 5b) . However, BAFF levels overall clearly tended to decrease with time after B cell return (Fig. 5b) . We next examined whether there was any correlation between circulating BAFF levels and percentage of CD19 mature naive subpopulations showed an inverse correlation with serum BAFF levels (r 2 5 0Á41 for both), as did post-GC B cells (r 2 5 0Á54; P < 0Á001 (Fig. 5c) . We also confirmed a lack of any strong correlations between BAFFR expression (MFI) and BAFF levels [18] (data not shown).
Neither the percentage of B cells positive for, nor expression of, TACI and BCMA showed any significant correlations with serum BAFF levels in any of the RA patients studied (data not shown).
Is there any correlation between BBR expression (MFI) and the time after B cell return in patients relapsing post-RTX?
As shown in Fig. 6a , expression of BAFFR (MFI) in the transitional but not mature naive subset showed a notable increase with time after repopulation (r 2 5 0Á53, P < 0Á001). Less significant was the increased expression with time in post-GC (r 2 5 0Á33, P < 0Á05), IgD -resting memory (r 2 5 0Á34, P < 0Á05) and plasmablasts (r 2 5 0Á41, P < 0Á01). There was no correlation between the MFI of TACI expression and time after repopulation in any of the B cell subsets studied. Interestingly, however, TACI expression (MFI) (Fig. 6b) could be seen to remain largely within normal limits after RTX treatment, whereas BAFFR expression remained below the normal range in all B cell subpopulations up to 7 months after B cell return (Fig. 6a) . in healthy controls (HC), pre-RTX patients and patients relapsing after RTX. Results for HC and pre-RTX patients were compared and results between the two patient groups relapsing at different intervals after B cell return were also compared. Lines on graphs represent median values and results were analysed using the Mann-Whitney U-test; *P < 0Á05; **P < 0Á01; ***P < 0Á001. [Colour figure can be viewed at wileyonlinelibrary.com]
Discussion
Observations in other autoimmune rheumatic diseases and data from animal models have suggested that the consequences of raised BAFF levels in the circulation may include lowering the threshold for autoreactive B cell survival and expansion, with promotion of autoantibody production. We therefore hypothesized that the timing of re-establishment of symptoms following B cell return to the periphery in patients with RA treated with RTX may be related to the BAFF/BBR axis. We found that in patients relapsing shortly after B cell repopulation, which is the situation where high BAFF levels are present due to the depletion of BAFF-binding B cells by RTX, returning B cells had very low levels of BAFFR. Repopulating naive B cells may therefore be unable to bind all the available BAFF until more B cells had exited the bone marrow and/or expanded into memory subsets or, as suggested in Ref. [2] , through high BAFF levels inducing increasing recycling of BAFFR. BAFF levels in serum from RA patients before RTX were higher than HC but generally within the normal range, as shown in previous studies [18, 29, 30] . It was clear, however, that at the higher levels of serum BAFF following RTX, the percentages of naive and of post-GC B cells positive for BAFFR were lower, with a significant negative correlation. As we did not see a correlation between serum BAFF levels and patient relapse (some patients relapse with high BAFF levels, some do not); we interpreted this to indicate that inappropriate signalling mediated by soluble BAFF was not responsible for driving relapse.
Following BCDT, B cells repopulate primarily from bone marrow-derived naive B cells, with regeneration of the memory B cell pool often delayed [15, 31, 32] . The high percentage of transitional B cells in patients relapsing closest to B cell return thus reflected the initial repopulation process, and mimics ontogeny. Increasing time to relapse was associated with a significant fall in the percentage of transitional naive B cells accompanied by an increase into the mature naive compartment, confirmed in longitudinal and post-GC memory B cells also increased with time after repopulation. We found that circulating memory B cell pools were low after RTX, even in patients relapsing ! 4 months after B cell return. It has been described that RTX induces a long-lasting effect on the memory cell subset in RA [20] and in lymphoma [33] , systemic lupus erythematosus (SLE) [34] and TTP [26] . We found that relapse occurred despite low circulating memory B cells, suggesting that long-lived memory B cells (and possibly CD20 -plasma cells) were the possible repository for disease memory for relapse after B cell return [23, 35] . In conventional B cell development it is thought that apoptosis is the 'default' programme for transitional naive B cells unless rescued by productive BAFFR (BR3)-mediated signalling [36] . Both the percentage and expression (MFI) of BAFFR on B cells returning post RTX was reduced compared to pre-RTX values in transitional and mature naive B cells and in memory B cell subsets, although tending to increase with time to relapse after B cell return, but remaining below the normal range in all B cell subpopulations during the course of follow-up. In our previous studies of patients with TTP treated with RTX, serum BAFF levels returned to within normal limits close to onset of repopulation. BAFFR expression (MFI) on all IgD/CD27-defined B cell subpopulations, however, remained well below the normal values for more than 5 years in patients maintaining remission [26] . This was associated with the lack of recovery of ADAMTS13 autoantibody production, suggesting a prolonged lack of (pathogenic) B cell differentiation to ISC in patients with long-lasting remissions, with low expression of BAFFR contributing to the lack of survival and/or further differentiation of ADAMTS13-committed B cells. Chronically raised serum BAFF has been suggested to exert a negative feedback on BAFFR expression, due perhaps to internalization or shedding, independently of exposure to B cell agonists [24, 37] . Following RTX, however, low BAFFR expression may be a repopulation phenomenon where newly exiting (from the bone marrow) B cells physiologically express less BAFFR, similar to what is seen in preterm neonates [38] . They are also expanding into an environment of high serum BAFF levels. Some RA patients relapsed soon after B cell return with predominantly early naive (transitional) B cells in the circulation, suggesting that in these patients, the disadvantages of low BAFFR expression/signalling were not limiting the onset of relapse [18] . Of the other two BBR, BCMA expression was low and relatively unchanged by RTX, with the percentage of TACI 1 memory B cells remaining significantly lower than HC following RTX.
Patients with RA showed a reduced percentage of TACI 1 B cells both in those with active disease pre-RTX and at relapse after RTX in all three memory B cell compartments. This suggests that disadvantages of low TACI expression are not translated into a lack of proinflammatory signalling. Whether this reflects a constitutive lack of upregulation of TACI in RA patients or down-regulation due to internalization or shedding of bound BAFF/APRIL heterodimers is not known. The role of TACI in B cell responses is complex, with contrasting functional outcomes depending on context, but mutation in TACI genes has been associated with some forms of common variable and IgA deficiency in man [39] . Co-ligation of TACI and proteoglycans is thought to be essential for class-switch recombination [40] . This has been attributed to the accompanying loss of inhibitory signals through TACI to BAFFR-and CD40-mediated signalling. Reduced percentage of TACI 1 memory B cell subsets may thus render B cells less responsive to inhibitory signalling through TACI.
Relapse coincident with or close to naive B cell re-entry to the periphery was not associated with prominent memory or plasmablast populations, and with greatly reduced percentages and expression of the main pro-survival BBR, namely BAFFR, by the newly exiting B cells. We also found no increases in percentage of BCMA 1 B cells. Coincident with differentiation into ISC, BCMA is acquired on mature B cells accompanied by loss of BAFFR expression, and has been described to be functional and responsible for mediating BAFF-induced survival of ISCs [2, 41] . BCMA expression can be increased on plasmablasts and memory B cells from patients with systemic lupus erythematosus (SLE) [25, 42, 43] and can also be expressed in transitional B cells, where it is associated with inappropriate naive B cell activation to ISC [25] . We found no differences in BCMA expression (% and MFI) between HC and pre-and post-RTX RA patients, however, with the exception of a slight increase in memory resting populations. In our previous studies of autoantibody kinetics and serological markers of B cell differentiation, we found that most of the ACPA specificities rising coincident with relapse after RTX appeared to be derived from resident memory B cells, with few new specificities arising. Rises in RhF and levels of a soluble marker of B cell differentiation to memory phenotype (sCD23) showed an incremental rise, which correlated with time to flare after B cell return [19] . In the current studies, precipitation of relapse in patients analysed ! 4 months after B cell return would seem to depend upon further recovery of the mature naive B cell pool with percentage of BAFFR 1 B cells approaching those of HC over time and increasing BAFFR expression. This suggests that a 'critical mass' of autoreactive B cells may be needed to trigger flare. The mechanism of relapse may therefore follow a more conventional pathway, with T cell-mediated selection occurring in secondary lymphoid organs or inflammatory sites.
In healthy individuals, further differentiation of B cells from transitional to mature naive stage is prevented if they are exposed to uncomplexed antigen through their BCR, even in the presence of both T-dependent and -independent co-stimulation. B cells exiting the BM in RA patients have been reported to have a high proportion of B cells expressing autoreactive BCR specific for citrullinated antigens and Fc of IgG (rheumatoid factors), suggesting alterations in the preimmune repertoire due to defective central tolerance checkpoints. Further it was shown that there were also defects in peripheral checkpoints with continued persistence of autoreactive naive B cells [44] [45] [46] . Survival of these newly exiting B cells may thus favour those with autoreactive BCR. Based on our results, we therefore propose that inappropriate signalling through a potentially autoreactive BCR rather than through BAFF may drive relapse.
In conclusion, aberrant B cell selection, expansion and differentiation to autoantibody production, combined with inappropriate T cell responses, can occur at different points within B cell maturation pathways which differ between human autoimmune diseases, thereby influencing the institution of effective therapies [47, 48] . Although we found changes over time in the expression of BBRs on the different B cell subpopulations in relation to timing of relapse in individual RA patients, most of the process appears independent of the BAFF/BBR system. The lack of clear success in clinical trials of agents to neutralize soluble BAFF in patients with RA may also be explained by our findings.
